Premium
Affordable access to innovative cancer medicines — don't forget the prices
Author(s) -
Ghinea Narcyz,
Lipworth Wendy
Publication year - 2016
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/mja15.01309
Subject(s) - citation , sociology , library science , medicine , computer science
"permission received via email Kerrie Harding\udEditorial Administrator, MJA, on 7 Apr16"On 17 September 2015, the much anticipated Senate report on the and specialist cancer drugs in Australia Availability of new, innovative was\udreleased.1 The inquiry preceding the report, which\udwas triggered by concerns about inadequate and\udinequitable access to cancer medicines, had\udattracted over 200 submissions from doctors,\udpatients, patient advocacy groups and government\uddecision makers.\udThe report addressed the health burden of cancer on\udour society; the impact on patients of delayed access to\udcancer medicines; and the challenges of assessing\udcost-effectiveness, particularly for rare cancers. It also\udfocused on ways of improving Australia’s processes of\udhealth technology assessment (HTA), by which we\uddetermine whether medicines are safe, effective and\udcost-effective.NHMRC project grant, App 108067